Dose escalation of biologics in Crohn's disease: critical review of observational studies.
Thomas R EinarsonBasil G BerezaXin Ying LeeFilippo LelliPublished in: Current medical research and opinion (2017)
A substantial proportion of patients receiving ADA or IFX for Crohn's disease require dose escalation after a short period of time.
Keyphrases